Vertex cleans up its pipeline; FDA grants priority review to Jakafi for GVHD
→ While AbbVie was stepping up to challenge Vertex on cystic fibrosis today, the Boston-based biotech was engaged in a little pipeline cleanup. Vertex execs say they decided to drop a drug called VX-210 after an independent monitoring committee concluded the Phase IIb was a bust. Vertex bought the drug a few years ago from BioAxone, paying only $10 million upfront and promising up to $90 million more — not something that will break the bank at Vertex.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
